Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
HOME > BUSINESS
BUSINESS
- Teijin Pharma Files Osteoporosis Drug Abaloparatide in Japan
May 29, 2020
- tella, Cenegenics Begin Clinical Trial of Stem Cell Therapy for COVID-19 in Mexico, Japan Study Planned in Autumn
May 29, 2020
- Sanofi Japan Introduces 2-Week-Rule before Getting Back to Full Operations after COVID-19 Emergency Lift
May 29, 2020
- Drug Makers Exploring “New Normal” in Post-COVID-19; Takeda Plans Major Changes
May 28, 2020
- Towa Voluntarily Recalls Pentasa Generics due to Inadequate Shipment Testing at Contract Manufacturer Nichi-Iko
May 28, 2020
- Japan SGLT2 Inhibitor Market Hits 100 Billion Yen after Weak Start: Jiho Estimate
May 27, 2020
- Fujifilm Eyes FY2020 Trial Launch for Liposome Drug-Keytruda Combo
May 27, 2020
- Shionogi Snaps Up Tetra after PII Alzheimer’s Study Completed
May 27, 2020
- Bayer’s Prostate Cancer Med Nubeqa Now Available in Japan
May 27, 2020
- Japan Pharma Market Tops 10 Trillion Yen for 5th Year Running in FY2019, Keytruda Surges to No.1: IQVIA
May 27, 2020
- Japan Pharma Market Up 0.2% in January-March: IQVIA
May 27, 2020
- TB Drug Deltyba Approved in Russia: Otsuka
May 26, 2020
- Tanabe Mitsubishi Gets Tenelia OK in Thailand
May 26, 2020
- Novartis Launches AMD Drug Beovu in Japan
May 26, 2020
- Daiichi Sankyo’s Enhertu Hits Japan Market for Breast Cancer
May 26, 2020
- Simon Lee to Lead ViiV Japan from June
May 26, 2020
- Sawai Ponders Possible Delay in Rollout of 4 Generic Brands After June Listing
May 26, 2020
- Takeda’s NSCLC Med Alunbrig Nabs Frontline Nod in US
May 26, 2020
- 90% of Drug Promotion Shifted to Remote Tools; Prudent Attitude Needed for New Launches amid COVID-19: IQVIA Official
May 25, 2020
- Enhertu Gets US FDA’s Orphan Status for Gastric Cancer
May 25, 2020
ページ
More than a year after Dupixent (dupilumab) became the first antibody therapy approved for COPD in Japan, drug makers are…
A few weeks ago, I had coffee with a very talented executive. Let’s call him Kenji. He has a great job, a big salary, and a solid team. But he was unhappy. He felt bored and wanted a new challenge.…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…